Back to Search Start Over

Diffusion-weighted imaging allows for downgrading mr bi-rads 4 lesions in contrast-enhanced mri of the breast to avoid unnecessary biopsy

Authors :
Thomas H. Helbich
Marco Moschetta
Nicoletta Troiano
Victor-Frederic Neuhaus
Barbara Krug
Hubert Bickel
Maria Adele Marino
Paola Clauser
Katja Pinker
Matthias Dietzel
Pascal A. T. Baltzer
Source :
Clin Cancer Res
Publication Year :
2021
Publisher :
American Association for Cancer Research Inc., 2021.

Abstract

Purpose: Diffusion-weighted imaging with the calculation of an apparent diffusion coefficient (ADC) has been proposed as a quantitative biomarker on contrast-enhanced MRI (CE-MRI) of the breast. There is a need to approve a generalizable ADC cutoff. The purpose of this study was to evaluate whether a predefined ADC cutoff allows downgrading of BI-RADS 4 lesions on CE-MRI, avoiding unnecessary biopsies. Experimental Design: This was a retrospective, multicentric, cross-sectional study. Data from five centers were pooled on the individual lesion level. Eligible patients had a BI-RADS 4 rating on CE-MRI. For each center, two breast radiologists evaluated the images. Data on lesion morphology (mass, non-mass), size, and ADC were collected. Histology was the standard of reference. A previously suggested ADC cutoff (≥1.5 × 10−3 mm2/second) was applied. A negative likelihood ratio of 0.1 or lower was considered as a rule-out criterion for breast cancer. Diagnostic performance indices were calculated by ROC analysis. Results: There were 657 female patients (mean age, 42; SD, 14.1) with 696 BI-RADS 4 lesions included. Disease prevalence was 59.5% (414/696). The area under the ROC curve was 0.784. Applying the investigated ADC cutoff, sensitivity was 96.6% (400/414). The potential reduction of unnecessary biopsies was 32.6% (92/282). Conclusions: An ADC cutoff of ≥1.5 × 10−3 mm2/second allows downgrading of lesions classified as BI-RADS 4 on breast CE-MRI. One-third of unnecessary biopsies could thus be avoided.

Details

Language :
English
Database :
OpenAIRE
Journal :
Clin Cancer Res
Accession number :
edsair.doi.dedup.....6ef497d8eb9390c3f72ecf18df07ead8